Recent Developments in Microbiome Therapeutics Recent-Developments-in-Microbiome-Therapeutics-Nov | Page 9

Lifestyle Related Diseases
With the fast paced and hectic lives we spend nowadays, lifestyle related diseases can be found in nearly all homes.
These diseases include type 2 diabetes, obesity, hypertension etc. Consumption of high-energy and high-fat foods
causes Metabolic Syndrome (MS), which affects nearly 35% of all US adults (as of 2012) 35 .
In March 2017, Ezaki Glico Co. Ltd. 36 , in collaboration with several researchers from Tokyo, published results
from a study 37 investigating the effects of probiotic Bifidobacterium treatment on MS. The group found that the
probiotic, Bifidobacterium animalis ssp. lactis GCL2505, improved metabolic disorders by reducing visceral fat
accumulation and improving glucose tolerance.
In another 2017 study 38 , researchers from China found that oral supplementation with the probiotics, Bifidobacterium
pseudocatenulatum LI09 and Bifidobacterium catenulatum LI10, attenuated D-galactosamine (D-GalN) induced
liver damage. The probiotics further conferred liver protection, reduced ileal mucosal injury and gut flora dysbiosis,
as well as alleviated the increase of cytokines in plasma.
In a study 39 of high-fat fed mice, a group of Finnish researchers from University of Turku found that oral
supplementation with Faecalibacterium prausnitzii improved hepatic health, decreased adipose tissue
inflammation, and increased muscle mass.
Besides the acne treatment mentioned earlier, AOBiome Therapeutics is also working towards developing treatments
for hypertension. Its lead product candidate, B244, a first-in-class, topical formulation of Nitrosomonas eutropha
D23, is currently undergoing Phase 2 Clinical Trial for testing safety and efficacy in individuals with either systolic
prehypertension or systolic Stage 1 hypertension 40 .
35 Moore J.X. et al (2017), Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health
and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis 14:160287. doi: 10.5888/pcd14.160287
36 
https://www.glico.com/global/
37 Aoki, R. et al (2017), A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic
disorders via microbiota modulation and acetate elevation. Scientific Reports 7, Article Number: 43522. doi: 10.1038/
srep43522
38 Fang D. et al (2017), Bifidobacterium pseudocatenulatum LI09 and Bifidobacterium catenulatum LI10 attenuate
D-galactosamine-induced liver injury by modifying the gut microbiota. Scientific Reports 7, Article Number: 8770. doi:
10.1038/s41598-017-09395-8
39 Munukka E. (2017), Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue
inflammation in high-fat fed mice. The ISME Journal 11: 1667-1679. doi: 10.1038/ismej.2017.24
40 
https://aobiome.com/news_item&item=140&title=AOBiome-Completes-Patient-Enrollment-In-Phase-2-Clinical-Trial-
Of-Lead-Candidate-B244-To-Treat-Elevated-Blood-Pressure
9
Recent Developments in Microbiome Therapeutics